ALG01

ALG01: sourced facts only. name: "ALG01 comprises a humanized PD-L1-targeting IgG1 fused with TROP2-targeting biparatopic VHHs at the C-terminal of the heavy chain, linked to exatecan via transglutaminase-mediated site-specific conjugation." [DOI:10.1158/1538-7445.am2025-2138]; target: "ALG01 comprises a humanized PD-L1-targeting IgG1 fused with TROP2-targeting biparatopic VHHs at the C-terminal of the heavy chain, linked to exatecan via transglutaminase-mediated site-specific conjugation." [DOI:10.1158/1538-7445.am2025-2138]; target: "ALG01 comprises a humanized PD-L1-targeting IgG1 fused with TROP2-targeting biparatopic VHHs at the C-terminal of the heavy chain, linked to exatecan via transglutaminase-mediated site-specific conjugation." [DOI:10.1158/1538-7445.am2025-2138]; developer: "Allygen Biologics, Shanghai, China." [DOI:10.1158/1538-7445.am2025-2138]; stage: "Furthermore, in a MC38-PDL1-TROP2 syngeneic model, ALG01 treatment led to complete tumor eradication in 7 of 8 mice, showing significantly superior efficacy compared to reference anti-TROP2 ADC and its combination with reference anti-PD-L1 antibody." [DOI:10.1158/1538-7445.am2025-2138]